<DOC>
	<DOCNO>NCT01938859</DOCNO>
	<brief_summary>The purpose AGTs-BD study compare treatment outcome safety profile different mood stabilizer combination treatment patient bipolar disorder , currently suffer depression episode .</brief_summary>
	<brief_title>Algorithm Guided Treatment Strategies Bipolar Depression</brief_title>
	<detailed_description>The AGTs-BD study randomize , open-label , rater-blind , multicenter study , include 8-week acute treatment ( Phase I ) , follow 24-week recurrence prevention treatment ( Phase II ) , 24-week relapse prevention treatment ( Phase III ) . Patients initially enter 4 week screen phase confirm randomization meet DSM-IV criterion bipolar I II disorder , currently depress Hamilton Depression Rating Scale-17 item ( HAM-D ) total score ≥17 . The protocol approve site ' appropriate institutional review board ethic committee . After screen , patient randomly allocate one three group : ( 1 ) lithium monotherapy ; ( 2 ) lithium plus quetiapine ; ( 3 ) lithium plus Traditional Chinese Medicine ( TCM ) name Shuganjieyu capsule ( SGJY , St. John 's wort acanthopanax senticosus combination ) . After phase I , patient meet stable remission , define HAM-D total score ≤7 Young Mania Rating Scale ( YMRS ) total score ≤10 two consecutive visit least 4 week , qualify phase II III . Patients remain allocated treatment 48 week treatment failure . The difference phase II phase III treatment dose could decrease ( within study range ) side-effects become troublesome phase III , phase II . All patient provide free care ( 3 visit ) investigator , period 3 month end study , order help make transition routine clinical care .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Age 18 65 year old ; Han Chinese ; Outpatient inpatient patient ; Patients meet DSMIV criterion bipolar I II disorder , currently depress , ascertain Mini International Neuropsychiatric Interview ( MINI ) HAMD total score≥17 , HAMD item 1 ( depressed mood ) score≥2 , YMRS total score≤10 baseline ; Written inform consent give ; Junior high school education , enough audiovisual ability accomplish visit ; Normally resident one country residential address , able followup . Bipolar disorder rapid cycling mixed episode ; Experienced DSMIVTR axis I disorder 6 month prior randomization ; Severe personality disorder , metal retardation , anorexia/bulimia nervosa ; Actively suicide ascertain research psychiatrist HAMD item 3 score≥3 ( suicidality ) ; Known history intolerance hypersensitivity medication involve study , include lithium , quetiapine SGJY capsule ; Female patient pregnant , plan pregnant breast feeding ; Severe medical neurological problem .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>bipolar disorder</keyword>
	<keyword>lithium</keyword>
	<keyword>quetiapine</keyword>
	<keyword>Medicine , Chinese Traditional</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>Recurrence</keyword>
</DOC>